PrecivityAD2 is a blood test cleared in 2026 to help evaluate Alzheimer's in adults age 40 and older with cognitive impairment. For people with mild cognitive impairment, it aligns closely with amyloid PET but cannot alone establish the cause.
Mild cognitive impairment means memory or thinking changes that are noticeable but do not prevent daily activities. PrecivityAD2 is an aid to evaluation, not a stand-alone diagnosis. Its value depends on clinical workup and follow-up testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does PrecivityAD2 measure?
- How accurate is it in cognitive impairment?
- Why does clearance from age 40 matter?
- What should people with MCI do next?
What does PrecivityAD2 measure?
PrecivityAD2 measures plasma amyloid-beta 42/40 and two forms of tau in blood. According to Medical News Today, the method is mass spectrometry and the markers are combined into an Amyloid Probability Score 2 from 0-100 mass spectrometry test description. The score estimates the likelihood of brain amyloid pathology linked to Alzheimer's.
It is ordered for symptomatic adults after cognitive concerns appear. The Alzheimer's Association reports that the FDA cleared the test on Aug. 20, 2026, for symptomatic adults aged 40 and older with cognitive impairment the FDA clearance announcement.
How accurate is it in cognitive impairment?
Independent validation in the ADNI cohort compared APS2 with amyloid PET in cognitively impaired people. As reported in npj Dementia from Nature, agreement reached AUC 0.95, with 91% accuracy, 90% sensitivity, and 92% specificity the ADNI validation results.
That performance meets the accuracy bar described in 2025 Alzheimer's Association blood-biomarker guidance. The Alzheimer's Drug Discovery Foundation reports the guidance applies only in specialty care for cognitively impaired patients. It also reserves PET- or spinal-fluid replacement for tests with at least 90% sensitivity and specificity.
Why does clearance from age 40 matter?
PrecivityAD2 is the first FDA-cleared Alzheimer's blood test for use down to age 40. FixFirst Health reports that Lumipulse, cleared in May 2025, and Elecsys pTau181, cleared in October 2025, were cleared only for ages 55 and older the age-40 clearance comparison. The younger age range matters because early-onset symptoms have many possible causes.
PharmaDeviceNews reports that cognitive symptoms in younger adults can resemble depression and that early-onset Alzheimer's is often mistaken for it. A positive blood result therefore does not by itself explain MCI. FDA labeling also limits the test to symptomatic evaluation. Medical News Today reports the test is not for asymptomatic screening and must be read with clinical workup because false positives and negatives affect diagnosis and treatment.
What should people with MCI do next?
For MCI care, the practical role is faster triage. Medical Xpress describes the next steps as PET or spinal-fluid testing and assessment for disease-modifying drugs that modestly slow early-stage decline, rather than stand-alone diagnosis.
Useful steps to discuss with a memory clinic include: Bring a family member or close contact to describe daily changes. Ask for the result in writing, with the follow-up plan and referral timeline.
- document symptoms, onset, medications, mood, sleep, and medical causes
- ask whether PrecivityAD2 fits the clinic's evaluation pathway
- ask what positive, negative, or uncertain scores would change next
- confirm plans for PET or spinal-fluid confirmation and treatment review
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Accuracy, Limits, and Evidence Gaps for People With Mild Cognitive Impairment
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Accuracy, Limits, and Evidence Gaps for People With Mild Cognitive Impairment
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Accuracy, Limits, and Evidence Gaps for People With Mild Cognitive Impairment
